Liraglutide for Islet GLP-1 in Type 1 and Type 2 Diabetes
This study is looking at how a medication called liraglutide (a GLP-1 receptor agonist) affects a substance in your body called islet GLP-1 in people with Type 1 or Type 2 diabetes. Researchers want to understand if controlling blood sugar and using liraglutide changes how islet GLP-1 works in people with and without beta cells (cells that make insulin). You might be able to join if you are 25-70 years old, have Type 1 or Type 2 diabetes treated with insulin, and your HbA1c (a measure of blood sugar control) is 10.0% or less. The study will measure changes in glucagon secretion (a hormone that raises blood sugar) after treatment with liraglutide. The current status of this study is unclear, and it plans to enroll 60 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It involves 60 participants and uses both liraglutide and saline injections (a placebo) in a single-blind manner, meaning you wouldn't know if you're getting the active drug or the placebo.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The main effects are measured after 30 days of treatment with liraglutide.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Adrian Vella, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatmentThe change in fasting glucagon secretion rate (saline vs. exendin 9-39) in the baseline study will be compared with the change in fasting glucagon secretion rate (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during fasting (-30 to 0 min) of each study day.
- Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutideThe change in glucagon secretion rate during hyperglycemia (saline vs. exendin 9-39) in the baseline study will be compared with the change (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during hyperglycemia (150 to 180 min) of each study day.